The stock of Beam Therapeutics Inc (BEAM) has gone down by -4.54% for the week, with a -3.52% drop in the past month and a -23.59% drop in the past quarter. The volatility ratio for the week is 0.72%, and the volatility levels for the past 30 days are 2.95% for BEAM. The simple moving average for the last 20 days is 0.52% for BEAM stock, with a simple moving average of -26.53% for the last 200 days.
Is It Worth Investing in Beam Therapeutics Inc (NASDAQ: BEAM) Right Now?
The stock has a 36-month beta value of 2.08. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BEAM is 89.62M, and at present, short sellers hold a 23.61% of that float. On June 17, 2025, the average trading volume of BEAM was 2.23M shares.
BEAM) stock’s latest price update
Beam Therapeutics Inc (NASDAQ: BEAM) has seen a rise in its stock price by 3.85 in relation to its previous close of 16.62. However, the company has experienced a -4.54% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-13 that Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with BofA Securities repeating the rating for BEAM by listing it as a “Buy.” The predicted price for BEAM in the upcoming period, according to BofA Securities is $42 based on the research report published on March 28, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see BEAM reach a price target of $40. The rating they have provided for BEAM stocks is “Sector Outperform” according to the report published on March 10th, 2025.
BEAM Trading at -1.61% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.04% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Bellon Christine, who sale 5,674 shares at the price of $18.35 back on Apr 01 ’25. After this action, Bellon Christine now owns 117,294 shares of Beam Therapeutics Inc, valued at $104,122 using the latest closing price.
Evans John M., the CEO of Beam Therapeutics Inc, sale 30,663 shares at $18.35 during a trade that took place back on Apr 01 ’25, which means that Evans John M. is holding 986,249 shares at $562,684 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -6.77 for the present operating margin
- 0.74 for the gross margin
The net margin for Beam Therapeutics Inc stands at -6.09. The total capital return value is set at -0.32. Equity return is now at value -38.04, with -27.41 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.22. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -30.35.
Currently, EBITDA for the company is -383.98 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 21.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.81.
Conclusion
To sum up, Beam Therapeutics Inc (BEAM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
